EMBARGOED UNTIL 4 P.M. ET, WEDNESDAY, FEBRUARY 23, 2022
Newswise — MINNEAPOLIS – To help neurologists, patients and their families understand the current evidence on the use of aducanumab to treat Alzheimer’s disease, the American Academy of Neurology (AAN) has issued an evidence-in-focus article, published in the February 23, 2022, online issue of Neurology®, the medical journal of the AAN. The article also includes a discussion of the safety, costs, administration, and quality-of-life issues related to aducanumab to provide people with a more detailed understanding of the new treatment.
An AAN evidence-in-focus article is a review of available studies, using a modified AAN process, to highlight the strength of the evidence for new therapies. More research is needed on aducanumab before any AAN guideline recommendations can be created.
“More than six million people in the…
